Eligibility: Bladder cancer patients who have biopsy confirmed non-muscle invasive bladder cancer (NMIBC) of the high-risk transitional cell carcinoma subtype (Ta, T1 or CIS) and have not yet been treated with BCG but are eligible for BCG therapy. Patients must also have adequate heart, lung, liver and kidney functions.
This study is a clinical trial to evaluate the safety and efficacy of the study drug ALT-803, a cytokine-based immunotherapeutic drug, in the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). ALT-803 is an investigational drug, which means that it has not been approved by the United States Food and Drug Administration (FDA), but the FDA has granted permission for ALT-803 to be tested in this study. Recently, the study sponsor (Altor BioScience Corporation) was granted FDA Fast Track Designation which expedites the development and review of drugs to treat serious conditions and fill unmet medical needs.
As part of this clinical trial, patients will be randomly chosen to receive either BCG plus the study drug ALT-803, or BCG alone. The study will include a screening visit, 6 treatment visits, and then 8 follow up visits every 3 months (starting from the time of first treatment) for a total participation of 24 months. Patients will receive 6 doses of the treatment, one treatment per week for 6 weeks. Study participants will also be observed for any adverse effects of the study medication, and any evidence of prostate cancer progression. There is limited data about the effects of ALT-803 on humans. The expected side effects of ALT-803 are similar to the drug Proleukin® (IL-2). The following side effects from ALT-803 are most likely to occur: weight gain, anemia, low blood pressure, flu-like symptoms, increased risk of infection, bruising, skin rash, weakness, headache, dizziness, vomiting, nausea, loss of appetite, and low blood electrolytes.
For more information, please contact our research coordinator at 516-535-4184 or email@example.com